Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.45 HKD | +3.76% | +25.00% | +11.53% |
04-15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
04-15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Business Summary
Number of employees: 444
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Ophthalmic Pharmaceutical Platform
100.0
%
| 185 | 100.0 % | 272 | 100.0 % | +47.28% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 185 | 100.0 % | 272 | 100.0 % | +47.28% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 53 | 31/07/18 |
Tim Ruan
DFI | Director of Finance/CFO | 38 | 11/01/23 |
Dong Hong Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 27/10/19 |
Zhao Peng Hu
BRD | Director/Board Member | 51 | 02/09/18 |
Ting Chan Chen
SEC | Corporate Secretary | 30 | 30/06/21 |
Qinglei Zuo
PRN | Corporate Officer/Principal | 40 | 31/12/20 |
Hong Ying Liu
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Li
BRD | Director/Board Member | 52 | 31/03/18 |
Yan Ling Cao
BRD | Director/Board Member | 39 | 17/06/19 |
Ting Yuk Wu
BRD | Director/Board Member | 69 | 22/06/20 |
Lian Yong Chen
CHM | Chairman | 62 | 22/05/18 |
Yumeng Wang
BRD | Director/Board Member | 33 | 18/03/21 |
Zhenyu Zhang
BRD | Director/Board Member | 50 | 07/04/22 |
Ye Liu
CEO | Chief Executive Officer | 53 | 31/07/18 |
Zhao Peng Hu
BRD | Director/Board Member | 51 | 02/09/18 |
Yi Ran Huang
BRD | Director/Board Member | 69 | 22/06/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 695,614,850 | 330,899,975 ( 47.57 %) | 0 | 47.57 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ALIMERA SCIENCES, INC. 2.19% | 1,144,945 | 2.19% | 4,465,286 $ |
100,221 | 0.20% | 2,071,568 $ |
Company contact information
Ocumension Therapeutics
No. 1858 Yinzhongnan Road Guoxiang Subdistrict
215000, Suzhou
+
http://www.ocumension.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.53% | 637M | |
+31.13% | 699B | |
+25.07% | 571B | |
-4.27% | 364B | |
+18.35% | 326B | |
+3.31% | 286B | |
+14.38% | 236B | |
+4.60% | 198B | |
-12.60% | 194B | |
-4.53% | 154B |
- Stock Market
- Equities
- 1477 Stock
- Company Ocumension Therapeutics